Finally, we investigated whether CD8β might constitute a useful marker in the clinical T-ALL setting, which seemed a particularly interesting hypothesis given the perinatal origin of CD8αβ+ γδ T cells and the pediatric nature of a majority of T-ALL cases36. This evidence concerns the gene CD8B and acute lymphoblastic leukemia.